APA

El Raziky M., Gamil M., Ashour M. K., Sameea E. A., Doss W., Hamada Y., Van Dooren G., DeMasi R., Keim S., Lonjon-Domanec I., Hammad R., Hashim M. S., Hassany M. & Waked I. (20171101). Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. : Journal of viral hepatitis.

Chicago

El Raziky M, Gamil M, Ashour M K, Sameea E A, Doss W, Hamada Y, Van Dooren G, DeMasi R, Keim S, Lonjon-Domanec I, Hammad R, Hashim M S, Hassany M and Waked I. 20171101. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. : Journal of viral hepatitis.

Harvard

El Raziky M., Gamil M., Ashour M. K., Sameea E. A., Doss W., Hamada Y., Van Dooren G., DeMasi R., Keim S., Lonjon-Domanec I., Hammad R., Hashim M. S., Hassany M. and Waked I. (20171101). Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. : Journal of viral hepatitis.

MLA

El Raziky M, Gamil M, Ashour M K, Sameea E A, Doss W, Hamada Y, Van Dooren G, DeMasi R, Keim S, Lonjon-Domanec I, Hammad R, Hashim M S, Hassany M and Waked I. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. : Journal of viral hepatitis. 20171101.